Evidence map›Paper›PMID 28465528›Full record

ArticleLeukemia2017

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.

J Yu, L Chen, Y Chen, M K Hasan, E M Ghia, L Zhang, R Wu, L Z Rassenti, G F Widhopf, Z Shen and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Role of the Ror family receptors in Wnt5a signaling.In vitro cellular & developmental biology. Animal · 2024
    Review
  9. Review
  10. Article
  11. Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen.Reports of biochemistry & molecular biology · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

J YuMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
L ChenMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
Y ChenMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
M K HasanMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
E M GhiaMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
L ZhangMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
R WuMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
L Z RassentiMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
G F WidhopfMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
Z ShenSection of Cell and Developmental Biology, University of California-San Diego, La Jolla, CA, USA.
S P BriggsSection of Cell and Developmental Biology, University of California-San Diego, La Jolla, CA, USA.
T J KippsMoores Cancer Center, University of California-San Diego, La Jolla, CA, USA.
Moores Cancer CenterUniversity of California, San Diego · US

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534
6 · The paper itself

Abstract

Wnt5a can activate Rho GTPases in chronic lymphocytic leukemia (CLL) cells by inducing the recruitment of ARHGEF2 to ROR1. Mass spectrometry on immune precipitates of Wnt5a-activated ROR1 identified 14-3-3ζ, which was confirmed by co-immunoprecipitation. The capacity of Wnt5a to induce ROR1 to complex with 14-3-3ζ could be blocked in CLL cells by treatment with cirmtuzumab, a humanized mAb targeting ROR1. Silencing 14-3-3ζ via small interfering RNA impaired the capacity of Wnt5a to: (1) induce recruitment of ARHGEF2 to ROR1, (2) enhance in vitro exchange activity of ARHGEF2 and (3) induce activation of RhoA and Rac1 in CLL cells. Furthermore, CRISPR/Cas9 deletion of 14-3-3ζ in ROR1-negative CLL cell-line MEC1, and in MEC1 cells transfected to express ROR1 (MEC1-ROR1), demonstrated that 14-3-3ζ was necessary for the growth/engraftment advantage of MEC1-ROR1 over MEC1 cells. We identified a binding motif (RSPS

Indexed as

14-3-3 ProteinsAdoptive TransferAmino Acid MotifsAnimalsBinding SitesCell ProliferationCells, CulturedChemotaxisDisease Models, AnimalDisease ProgressionHumansLeukemia, Lymphocytic, Chronic, B-CellMiceMice, KnockoutProtein BindingReceptor Tyrosine Kinase-like Orphan Receptors14-3-3 ProteinsARHGEF2 protein, humanReceptor Tyrosine Kinase-like Orphan ReceptorsRho Guanine Nucleotide Exchange FactorsROR1 protein, humanWnt-5a ProteinWNT5A protein, human

Identifiers

PMID28465528
PMCPMC5670032
OpenAlexW2611085565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.